Back to Feed
Stem cell research & therapy|Peer-Reviewed
Safety and feasibility of intravenous fresh adipose-derived mesenchymal stem cells in secondary progressive multiple sclerosis: phase I/IIa clinical results.
Fahimeh Lavi Arab, Forouzan Yousefi, Hojjat Naderi-Meshkin, Mahdi Mirahmadi, Fatemeh Faraji, Karim Nikkhah, Houshang Amiri, Marjan Erfani, Fatemeh Ayoobi, Nafiseh Sadat Tabasi, Ali Nikkhah, Mahmoud Mahmoudi
Abstract
Mesenchymal stem cells (MSCs) hold substantial promise in regenerative medicine owing to their immunomodulatory, neuroregenerative, and self-renewal properties. Adipose tissue (AT) serves as an optimal MSC source due to its high yield and rapid proliferation. This study evaluated the safety and exploratory clinical effects of non-cryopreserved, culture-expanded autologous AT-MSCs in patients with secondary progressive multiple sclerosis (SPMS).
Keywords
<Keyword MajorTopicYN="N">AT-MSCsClinical trialCulture-expanded adipose tissue mesenchymal stem cellsMSNon-cryopreservedSPMSSecondary progressive multiple sclerosis